Gammaherpesviruses and lymphoproliferative disorders

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 349-372

  Cesarman, Ethel ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acquired immunodeficiency syndrome; AIDS; Cancer; EBV; Epstein Barr virus; HHV 8; HIV; Human herpesvirus 8; Human immunodeficiency virus; Kaposi's sarcoma herpesvirus; KSHV; Lymphoma; Multicentric Castleman's disease

Indexed keywords

ANIMAL; HERPES VIRUS; HERPES VIRUS INFECTION; HOST PATHOGEN INTERACTION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PATHOLOGY; REVIEW; VIROLOGY; VIRUS INFECTION;

ANIMALS; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; TUMOR VIRUS INFECTIONS;

EID: 84897020077     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104656     Document Type: Article

References (167)

1. Burkitt D. 1958. A sarcoma involving the jaws in African children. Br. J. Surg. 46:218-23
2. Magrath I. 2013. An introduction to Burkitt lymphoma. In Burkitts Lymphoma, ed. ES Robertson, pp. 1-33. New York: Springer
3. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitts lymphoma. Lancet 1:702-3
4. Epstein MA, Achong BG. 1973. Letter: Epstein-Barr virus and infectious mononucleosis. Lancet 2:1437-38
5. Giulino-Roth L, Cesarman E. 2013. Molecular biology of Burkitt lymphoma. In Burkitts Lymphoma, ed. ES Robertson, pp. 211-26. New York: Springer
6. Love C, Sun Z, Jima D, Li G, Zhang J, et al. 2012. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44:1321-25
7. Richter J, Schlesner M, Hoffmann S, KreuzM, Leich E, et al. 2012. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44:1316-20
8. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, et al. 2012. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116-20
9. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, et al. 2009. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J. Clin. Oncol. 27:5039-48
10. Dunleavy K, Wilson WH. 2010. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. J. Clin. Oncol. 28:e260
11. Chadburn A, Noy A, Lee JY, Hyjek E, Banham AH, et al. 2010. Reply to K. Dunleavy et al. J. Clin. Oncol. 28:e261-62
12. Pasqualucci L. 2013. The genetic basis of diffuse large B-cell lymphoma. Curr. Opin. Hematol. 20:336-44
13. Giulino L, Mathew S, Ballon G, Chadburn A, Barouk S, et al. 2011. A20 (TNFAIP3) genetic alterations in EBV-Associated AIDS-related lymphoma. Blood 117:4852-54
14. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al., eds. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, Fr.: IARC
15. Kluin PM, Harris NL, Stein H, Leoncini L, Raphael M, et al. 2008. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. See Ref. 14, pp. 265-66
16. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. 2006. Molecular diagnosis of Burkitts lymphoma. N. Engl. J. Med. 354:2431-42
17. HummelM, Bentink S, Berger H, KlapperW, Wessendorf S, et al. 2006.Abiologic definition of Burkitts lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354:2419-30
18. Hu E, Hufford S, Lukes R, Bernstein-Singer M, Sobel G, et al. 1988. Third-world Hodgkins disease at Los Angeles County-University of Southern California Medical Center. J. Clin. Oncol. 6:1285-92
19. Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, et al. 2003. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the greater San Francisco Bay Area, 1988-1998. Cancer 98:300-9
20. Carbone A, Gloghini A, Serraino D, Spina M. 2009. HIV-Associated Hodgkin lymphoma. Curr. Opin. HIV AIDS 4:3-10
21. Raphael M, Said J, Borisch B, Cesarman E, HarrisNL. 2008. Lymphomas associated with HIV infection. See Ref. 14, pp. 340-42
22. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, et al. 1997. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89:1413-20
23. Stein H, Harris NL, Campo E. 2008. Plasmablastic lymphoma. See Ref. 14, pp. 256-57
24. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. 2008. Post-transplant lymphoproliferative disorders. See Ref. 14, pp. 343-49
25. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, et al. 1988. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol. 133:173-92
26. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, et al. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552-65
27. Vakiani E, Nandula SV, Subramaniyam S, Keller CE, Alobeid B, et al. 2007. Cytogenetic analysis of B-cell posttransplant lymphoproliferations validates the World Health Organization classification and suggests inclusion of florid follicular hyperplasia as a precursor lesion. Hum. Pathol. 38:315-25
28. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, et al. 1998. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J. Clin. Oncol. 16:2052-59
29. Akashi K, Mizuno S. 2000. Epstein-Barr virus-infected natural killer cell leukemia. Leuk. Lymphoma 40:57-66
30. Aozasa K, Takakuwa T, Hongyo T, Yang WI. 2008. Nasal NK/T-cell lymphoma: epidemiology and pathogenesis. Int. J. Hematol. 87:110-17
31. Quintanilla-Martinez L, Kimura H, Jaffe ES. 2008. EBV-positive T-cell lymphoproliferative disorders of childhood. See Ref. 14, pp. 278-80
32. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, et al. 2011. Primary immunodeficiency diseases: an update on the classification from the InternationalUnion of Immunological Societies Expert Committee for Primary Immunodeficiency. Front. Immunol. 2:54
33. Leechawengwongs E, Shearer WT. 2012. Lymphoma complicating primary immunodeficiency syndromes. Curr. Opin. Hematol. 19:305-12
34. Filipovich AH, Mathur A, Kamat D, Shapiro RS. 1992. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res. 52:S5465-67
35. Shapiro RS. 2011. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am. J. Hematol. 86:48-55
36. Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE, Riminton S. 2010. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 116:1228-34
37. VanKrieken JH, Onciu M, Elenitoba-Johnson KSJ, Jaffe ES. 2008. Lymphoproliferative diseases associated with primary immune disorders. See Ref. 14, pp. 336-39
38. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4:757-68
39. Klein E, Kis LL, Klein G. 2007. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26:1297-305
40. Kelly G, Bell A, Rickinson A. 2002. Epstein-Barr virus-Associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 8:1098-104
41. Kelly GL, LongHM, Stylianou J, ThomasWA, LeeseA, et al. 2009. An Epstein-Barr virus anti-Apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 5:e1000341
42. Komano J, Maruo S, Kurozumi K, Oda T, Takada K. 1999. Oncogenic role of Epstein-Barr virus- encoded RNAs in Burkitts lymphoma cell line Akata. J. Virol. 73:9827-31
43. Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT. 2000. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J. Virol. 74:10223-28
44. Swaminathan S. 2008. Noncoding RNAs produced by oncogenic human herpesviruses. J. Cell. Physiol. 216:321-26
45. Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, et al. 2000. Epstein-Barr virus-encoded poly(A)- RNA supports Burkitts lymphoma growth through interleukin-10 induction. EMBO J. 19:6742-50
46. Lopes LF, Ruiz Miyazawa KW, de Almeida ERD, Serafim KG, de Almeida Gualtieri K, et al. 2013. Epstein-Barr Virus (EBV) microRNAs: involvement in cancer pathogenesis and immunopathology. Int. Rev. Immunol. 32:271-81
47. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, et al. 2006. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2:e23
48. Xing L, Kieff E. 2007. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J. Virol. 81:9967-75
49. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. 2010. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 6:e1001063
50. Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, et al. 1997. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposis sarcoma-Associated herpesvirus human herpesvirus-8. Blood 90:1186-91
51. SzekelyL, Chen F, TeramotoN, Ehlin-HenrikssonB, Pokrovskaja K, et al. 1998. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-Associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. Gen. Virol. 79:1445-52
52. Rea D, Delecluse HJ, Hamilton-Dutoit SJ, Marelle L, Joab I, et al. 1994. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non- Hodgkins lymphomas. French Study Group of Pathology for HIV-Associated Tumors. Ann. Oncol. 5(Suppl. 1):113-16
53. Kieff E, Rickinson A. 2007. Epstein-Barr virus and its replication. In Fields Virology, ed. B Fields, D Knipe, H PM, pp. 2603-55. Philadelphia: Wolters Kluwer
54. Wilson JB, Bell JL, Levine AJ. 1996. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15:3117-26
55. Humme S, Reisbach G, Feederle R, Delecluse HJ, Bousset K, et al. 2003. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. USA 100:10989-94
56. Kennedy G, Komano J, Sugden B. 2003. Epstein-Barr virus provides a survival factor to Burkitts lymphomas. Proc. Natl. Acad. Sci. USA 100:14269-74
57. Yin Q, Flemington EK. 2006. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 346:385-93
58. Dalla-Favera R, Bregni M, Erickson M, Patterson D, Gallo RC, Croce CM. 1982. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 79:7824-27
59. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, et al. 1991. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88:5413-17
60. Nakamura H, Said JW, Miller CW, Koeffler HP. 1993. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood 82:920-26
61. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκrecombination signal binding protein. Proc. Natl. Acad. Sci. USA 91:7568-72
62. Hsieh JJ, Hayward SD. 1995. Masking of the CBF1/RBPJκ transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268:560-63
63. WangD, LiebowitzD, Kieff E. 1985.AnEBVmembrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-40
64. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA 95:11963-68
65. Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, et al. 2012. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148:739-51
66. Kieser A, Kilger E, Gires O, UeffingM, Kolch W, Hammerschmidt W. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade.EMBOJ. 16:6478-85
67. Kilger E, Kieser A, Baumann M, Hammerschmidt W. 1998. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17:1700-9
68. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS. 1999. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1023-35
69. Guasparri I, Bubman D, Cesarman E. 2008. EBV LMP2A affects LMP1-mediated NF-κB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood 111:3813-20
70. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposis sarcoma-Associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N. Engl. J. Med. 332:1186-91
71. Nador RG, Cesarman E, Chadburn A, DawsonDB, Ansari MQ, et al. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposis sarcoma-Associated herpesvirus. Blood 88:645-56
72. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. 2004. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma.Am. J. Surg. Pathol. 28:1401-16
73. Matolcsy A, Nador RG, Cesarman E, Knowles DM. 1998. ImmunoglobulinVH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cellmaturation. Am. J. Pathol. 153:1609-14
74. KleinU, Gloghini A, GaidanoG, Chadburn A, Cesarman E, et al. 2003. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-21
75. Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, et al. 2003. Kaposis sarcoma-Associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc. Natl. Acad. Sci. USA 100:10399-404
76. Ballon G, Cesarman E. 2006. Castlemans disease. In Viral and Immunological Malignancies, ed. PA Volberding, J Palefsky. Hamilton, Can.: Decker
77. Waterston A, Bower M. 2004. Fifty years of multicentric Castlemans disease. Acta Oncol. 43:698-704
78. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, et al. 1995. Kaposis sarcoma- associated herpesvirus-like DNA sequences in multicentric Castlemans disease. Blood 86:1275-80
79. Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, et al. 2002. Castlemans disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am. J. Hematol. 69:119-26
80. Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T, et al. 2001. HHV-8 infection status of AIDSunrelated and AIDS-Associated multicentric Castlemans disease. Pathol. Int. 51:671-79
81. Dupin N, Diss TL, Kellam P, TulliezM, DuMQ, et al. 2000. HHV-8 is associated with a plasmablastic variant ofCastleman disease that is linked toHHV-8-positive plasmablastic lymphoma. Blood 95:1406-12
82. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, et al. 1999. Distribution of human herpesvirus- 8 latently infected cells in Kaposis sarcoma, multicentric Castlemans disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. USA 96:4546-51
83. Du MQ, Liu H, Diss TC, YeH, Hamoudi RA, et al. 2001. Kaposi sarcoma-Associated herpesvirus infects monotypic (IgM?) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130-36
84. ParraviciniC, CorbellinoM, Paulli M, MagriniU, LazzarinoM, et al. 1997. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castlemans disease. Am. J. Pathol. 151:1517-22
85. Cannon JS, Nicholas J, Orenstein JM, Mann RB, Murray PG, et al. 1999. Heterogeneity of viral IL-6 expression in HHV-8-Associated diseases. J. Infect. Dis. 180:824-28
86. Staskus KA, Sun R, MillerG, Racz P, Jaslowski A, et al. 1999. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposis sarcoma, primary effusion lymphoma, and multicentric Castlemans disease. J. Virol. 73:4181-87
87. Menke DM, Chadbum A, Cesarman E, Green E, Berenson J, et al. 2002. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. Am. J. Clin. Pathol. 117:268-75
88. Uldrick TS, WangV, OMahonyD, AlemanK, WyvillKM, et al. 2010. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-Associated herpesvirus and HIV but without multicentric Castleman disease. Clin. Infect. Dis. 51:350-58
89. Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, et al. 2002. KSHV- and EBV-Associated germinotropic lymphoproliferative disorder. Blood 100:3415-18
90. Ashihara E, Shimazaki C, Hirai H, Inaba T, Hasegawa G, et al. 2001. Human herpes virus 8-negative primary effusion lymphoma in a patient with a ventriculoperitoneal shunt tube. Int. J. Hematol. 74:327-32
91. Paner GP, Jensen J, Foreman KE, Reyes CV. 2003. HIV and HHV-8 negative primary effusion lymphoma in a patient with hepatitis C virus-related liver cirrhosis. Leuk. Lymphoma 44:1811-14
92. Matsumoto Y, Nomura K, Ueda K, Satoh K, Yasuda N, et al. 2005. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk. Lymphoma 46:415-19
93. Tsagarakis NJ, Argyrou A, Gortzolidis G, Kentrou N, Papadhimitriou SI, et al. 2009. Report of an HIV and HHV-8 negative case of primary effusion lymphoma with idiopathic T4 lymphocytopenia. Int. J. Hematol. 90:94-98
94. Saini N, Hochberg EP, Linden EA, Jha S, Grohs HK, Sohani AR. 2013. HHV8-negative primary effusion lymphoma of B-cell lineage: two cases and a comprehensive review of the literature. Case Rep. Oncol. Med. 2013:292301
95. Xia T, OHara A, Araujo I, Barreto J, Carvalho E, et al. 2008. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by EBV-miR-BHRF1-3. Cancer Res. 68:1436-42
96. Gottwein E, CorcoranDL, MukherjeeN, Skalsky RL, HafnerM, et al. 2011. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10:515-26
97. Carbone A, GaidanoG, Gloghini A, Larocca LM, Capello D, et al. 1998. Differential expression of BCL- 6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkins lymphomas. Blood 91:747-55
98. Radkov SA, Kellam P, Boshoff C. 2000. The latent nuclear antigen of Kaposi sarcoma-Associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6:1121-27
99. Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-94
100. Fujimuro M, Hayward SD. 2004. Manipulation of glycogen-synthase kinase-3 activity in KSHVassociated cancers. J. Mol. Med. 82:223-31
101. Bubman D, Guasparri I, Cesarman E. 2007. Deregulation of c-Myc in primary effusion lymphoma by Kaposis sarcoma herpesvirus latency-Associated nuclear antigen. Oncogene 26:4979-86
102. Renne R, Barry C, Dittmer D, Compitello N, Brown PO, GanemD. 2001. Modulation of cellular and viral gene expression by the latency-Associated nuclear antigen ofKaposis sarcoma-Associated herpesvirus. J. Virol. 75:458-68
103. Bajaj BG, Verma SC, Lan K, Cotter MA, Woodman ZL, Robertson ES. 2006. KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology 351:18-28
104. Verma SC, Borah S, Robertson ES. 2004. Latency-Associated nuclear antigen of Kaposis sarcoma- associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J. Virol. 78:10348-59
105. An J, Lichtenstein AK, Brent G, RettigMB. 2002. The Kaposi sarcoma-Associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-Associated nuclear antigen and the AP1 response element. Blood 99:649-54
106. Di Bartolo DL, Cannon M, Liu YF, Renne R, Chadburn A, et al. 2008. KSHV LANA inhibits TGF-β signaling through epigenetic silencing of the TGF-βtype II receptor. Blood 111:4731-40
107. Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, et al. 1997. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposis sarcoma-Associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-Associated nuclear antigen. J. Virol. 71:5915-21
108. Godden-Kent D, Talbot SJ, Boshoff C, Chang Y, Moore P, et al. 1997. The cyclin encoded by Kaposis sarcoma-Associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J. Virol. 71:4193-98
109. Li M, Lee H, Yoon D-W, Albrecht J-C, Fleckenstein B, Jung J. 1997. Kaposis sarcoma-Associated herpesvirus encodes a functional cyclin. J. Virol. 71:1984-91
110. Ellis M, Chew YP, Fallis L, Freddersdorf S, Boshoff C, et al. 1999. Degradation of p27Kip cdk inhibitor triggered by Kaposis sarcoma virus cyclin-cdk6 complex. EMBO J. 18:644-53
111. Mann DJ, Child ES, Swanton C, Laman H, Jones N. 1999. Modulation of p27Kip1 levels by the cyclin encoded by Kaposis sarcoma-Associated herpesvirus. EMBO J. 18:654-63
112. Verschuren EW, Klefstrom J, Evan GI, Jones N. 2002. The oncogenic potential of Kaposis sarcoma- associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2:229-41
113. Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. 2004. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 64:581-89
114. Cuomo ME, Knebel A, Morrice N, Paterson H, Cohen P, Mittnacht S. 2008. p53-driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nat. Cell Biol. 10:723-30
115. Sarek G, Jarviluoma A, MooreHM, Tojkander S, Vartia S, et al. 2010. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathog. 6:e1000818
116. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-21
117. Chaudhary PM, JasminA, EbyMT, Hood L. 1999. Modulation of the NF-κB pathway by virally encoded death effector domains-containing proteins. Oncogene 14:5738-46
118. Matta H, Chaudhary PM. 2004. Activation of alternative NF-κB pathway by human herpes virus 8- encoded Fas-Associated death domain-like IL-1β-converting enzyme inhibitory protein (vFLIP). Proc. Natl. Acad. Sci. USA 101:9399-404
119. Guasparri I, Wu H, Cesarman E. 2006. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. EMBO Rep. 7:114-19
120. Field N, Low W, Daniels M, Howell S, Daviet L, et al. 2003. KSHV vFLIP binds to IKK-γto activate IKK. J. Cell Sci. 116:3721-28
121. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025-32
122. Guasparri I, Keller SA, Cesarman E. 2004.KSHVvFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199:993-1003
123. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. 2005. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 105:2510-18
124. Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, et al. 2009. FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 11:1355-62
125. Chugh P, Matta H, Schamus S, Zachariah S, Kumar A, et al. 2005. Constitutive NFκB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc. Natl. Acad. Sci. USA 102:12885-90
126. Ballon G, Chen K, Perez R, Tam W, Cesarman E. 2011. Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J. Clin. Investig. 121:1141-53
127. Ahmad A, Groshong JS, Matta H, Schamus S, Punj V, et al. 2010. Kaposis sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. Cancer Biol. Ther. 10:1033-40
128. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. 2003. NF-κB inhibits gammaherpesvirus lytic replication. J. Virol. 77:8532-40
129. de Oliveira DE, Ballon G, Cesarman E. 2010. NF-κB signaling modulation by EBV and KSHV. Trends Microbiol. 18:248-57
130. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. 2001. Kaposis sarcoma-Associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75:429-38
131. Lubyova B, Kellum MJ, Frisancho AJ, Pitha PM. 2004. Kaposis sarcoma-Associated herpesvirus- encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J. Biol. Chem. 279:7643-54
132. Moore PS, Boschoff C, Weiss RA, Chang Y. 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-44
133. Molden J, ChangY, You Y, Moore PS, Goldsmith MA. 1997.AKaposis sarcoma-Associated herpesvirus- encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J. Biol. Chem. 272:19625-31
134. Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan XY, et al. 1997. Kaposis sarcoma-Associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 3:287-92
135. Chandriani S, Ganem D. 2010. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposis sarcoma-Associated herpesvirus. J. Virol. 84:5565-73
136. Sadler R, WuL, Forghani B, Renne R, ZhongW, et al. 1999. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposis sarcoma-Associated herpesvirus. J. Virol. 73:5722-30
137. Li H, Komatsu T, Dezube BJ, Kaye KM. 2002. The Kaposis sarcoma-Associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J. Virol. 76:11880-88
138. McCormick C, Ganem D. 2005. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307:739-41
139. Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Azumi N, et al. 1998. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposis sarcoma-Associated herpesvirus) transforming gene. J. Virol. 72:4980-88
140. Kliche S, Nagel W, Kremmer E, Atzler C, Ege A, et al. 2001. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol. Cell 7:833-43
141. Gandy SZ, Linnstaedt SD, Muralidhar S, Cashman KA, Rosenthal LJ, Casey JL. 2007. RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication. J. Virol. 81:13544-51
142. Lee H, Guo J, Li M, Choi JK, DeMaria M, et al. 1998. Identification of an immunoreceptor tyrosinebased activation motif of K1 transforming protein of Kaposis sarcoma-Associated herpesvirus. Mol. Cell. Biol. 18:5219-28
143. Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF. 2003. Activation of mitogen-Activated protein kinase and NF-κB pathways by a Kaposis sarcoma-Associated herpesvirus K15 membrane protein. J. Virol. 77:9346-58
144. Sharp TV, Wang HW, Koumi A, Hollyman D, Endo Y, et al. 2002. K15 protein of Kaposis sarcoma- associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J. Virol. 76:802-16
145. Lee H, Veazey R, Williams K, Li M, Guo J, et al. 1998. Deregulation of cell growth by the K1 gene of Kaposis sarcoma-Associated herpesvirus. Nat. Med. 4:435-40
146. Prakash O, Tang ZY, Peng X, Coleman R, Gill J, et al. 2002. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. J. Natl. Cancer Inst. 94:926-35
147. Tomlinson CC, Damania B. 2004. The K1 protein of Kaposis sarcoma-Associated herpesvirus activates the Akt signaling pathway. J. Virol. 78:1918-27
148. Prakash O, Swamy OR, Peng X, Tang ZY, Li L, et al. 2005. Activation of Src kinase Lyn by the Kaposi sarcoma-Associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 105:3987-94
149. Choi JK, Lee BS, Shim SN, Li M, Jung JU. 2000. Identification of the novel K15 gene at the rightmost end of the Kaposis sarcoma-Associated herpesvirus genome. J. Virol. 74:436-46
150. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. 2005. Kaposis sarcoma-Associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. USA 102:5570-75
151. Samols MA, Hu J, Skalsky RL, Renne R. 2005. Cloning and identification of a microRNA cluster within the latency-Associated region of Kaposis sarcoma-Associated herpesvirus. J. Virol. 79:9301-5
152. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, et al. 2005. Identification of microRNAs of the herpesvirus family. Nat. Methods 2:269-76
153. Grundhoff A, Sullivan CS, Ganem D. 2006. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12:733-50
154. Gottwein E. 2012. Kaposis sarcoma-Associated herpesvirus microRNAs. Front. Microbiol. 3:165
155. Lei X, Bai Z, Ye F, Xie J, Kim CG, et al. 2010. Regulation ofNF-κB inhibitor IκBαand viral replication by a KSHV microRNA. Nat. Cell Biol. 12:193-99
156. Gottwein E, Cullen BR. 2010. A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J. Virol. 84:5229-37
157. Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, et al. 2007. Kaposis sarcoma-Associated herpesvirus encodes an ortholog of miR-155. J. Virol. 81:12836-45
158. Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, et al. 2007. A viral microRNA functions as an orthologue of cellular miR-155. Nature 450:1096-99
159. Dahlke C, Maul K, Christalla T, Walz N, Schult P, et al. 2012. A microRNA encoded by Kaposi sarcoma-Associated herpesvirus promotes B-cell expansion in vivo. PLoS ONE 7:e49435
160. Lin X, Li X, Liang D, Lan K. 2012. MicroRNAs and unusual small RNAs discovered in Kaposis sarcoma-Associated herpesvirus virions. J. Virol. 86:12717-30
161. Haecker I, Gay LA, Yang Y, Hu J, Morse AM, et al. 2012. Ago HITS-CLIP expands understanding of Kaposis sarcoma-Associated herpesvirus miRNA function in primary effusion lymphomas. PLoS Pathog. 8:e1002884
162. DiNardo CD, Tsai DE. 2010. Treatment advances in posttransplant lymphoproliferative disease. Curr. Opin. Hematol. 17:368-74
163. Li N, Thompson S, Schultz DC, ZhuW, Jiang H, et al. 2010. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS ONE 5:e10126
164. Cesarman E. 2011. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 305:163-74
165. Ambinder RF, Cesarman E. 2007. Clinical and pathological aspects of EBV and KSHV infection. In Human Herpesviruses, ed. A Arvin, G Campadelli-Fiume, E Mocarski, PS Moore, B Roizman, et al., pp. 885-903. Cambridge, UK: Cambridge Univ. Press
166. Sun SC, Cesarman E. 2011. NF-κB as a target for oncogenic viruses. Curr. Top. Microbiol. Immunol. 349:197-244
167. Cesarman E, Mesri EA. 2006. Pathogenesis of viral lymphomas. In Hodgkins and Non-Hodgkins Lymphoma, ed. JP Leonard, MC Coleman, pp. 49-88. New York: Springer